These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26104577)

  • 21. Baseline 18 F-FDG PET/CT May Portend the Prognosis of Patients With Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma After First-Line Treatment.
    Pan Q; Cao X; Luo Y; Li J; Li F
    Clin Nucl Med; 2022 Nov; 47(11):954-960. PubMed ID: 35961637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical features of 16 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].
    Wang JJ; Jing HM; Shen HW; Xu JS; Li M; Gao ZF; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1494-8. PubMed ID: 21176358
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Hamilos G; Zervas K; Symeonidis A; Kouvatseas G; Roussou P; Gika D; Karmiris T; Bourantas K; Zomas A; Mitsouli C; Xilouri I; Vervessou E; Matsis K; Anagnostopoulos N; Economopoulos T;
    Ann Oncol; 2003 Aug; 14(8):1299-305. PubMed ID: 12881396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
    Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
    JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
    Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
    Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases].
    Chen Y; Zhang F; Wu HM; Luo XL; Zhang KP; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2021 Dec; 50(12):1346-1352. PubMed ID: 34865422
    [No Abstract]   [Full Text] [Related]  

  • 27. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
    Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
    J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
    Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
    Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Poulain S; Roumier C; Bertrand E; Renneville A; Caillault-Venet A; Doye E; Geffroy S; Sebda S; Nibourel O; Nudel M; Herbaux C; Renaud L; Tomowiak C; Guidez S; Tricot S; Roche-Lestienne C; Quesnel B; Preudhomme C; Leleu X
    Clin Cancer Res; 2017 Oct; 23(20):6325-6335. PubMed ID: 28754818
    [No Abstract]   [Full Text] [Related]  

  • 30. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.
    Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ
    Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
    Kristinsson SY; Eloranta S; Dickman PW; Andersson TM; Turesson I; Landgren O; Björkholm M
    Am J Hematol; 2013 Jan; 88(1):60-5. PubMed ID: 23165980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia.
    Cho JH; Shim JH; Yoon SE; Kim HJ; Kim SH; Ko YH; Lee ST; Kim K; Kim WS; Kim SJ
    Korean J Intern Med; 2021 May; 36(3):668-678. PubMed ID: 32791817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemia.
    Xiong W; Wang Z; Wang T; Yu Y; Huang Y; Sun H; Chen J; Lyu R; Wang H; Yan Y; Wang Q; Liu W; An G; Sui W; Huang W; Zou D; Xiao Z; Wang J; Ouyang G; Qiu L; Yi S
    Front Immunol; 2023; 14():1171539. PubMed ID: 37234167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.
    García-Sanz R; Dogliotti I; Zaccaria GM; Ocio EM; Rubio A; Murillo I; Escalante F; Aguilera C; García-Mateo A; García de Coca A; Hernández R; Dávila J; Puig N; García-Álvarez M; Chillón MDC; Alcoceba M; Medina A; González de la Calle V; Sarasquete ME; González M; Gutiérrez NC; Jiménez C
    Br J Haematol; 2021 Mar; 192(5):843-852. PubMed ID: 32780894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
    Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
    Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Waldenström macroglobulinemia.
    Vijay A; Gertz MA
    Blood; 2007 Jun; 109(12):5096-103. PubMed ID: 17303694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
    Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
    Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR4-targeted PET imaging using
    Muz B; Bandara N; Mpoy C; Sun J; Alhallak K; Azab F; Rogers BE; Azab AK
    Cancer Biol Ther; 2020; 21(1):52-60. PubMed ID: 31571524
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports.
    Elba S; Castellino A; Soriasio R; Castellino C; Bonferroni M; Mattei D; Strola G; Drandi D; Mordini N; Foglietta M; Rapezzi D; Celeghini I; Grasso M; Giordano F; Fraternali Orcioni G; Massaia M
    J Med Case Rep; 2020 Jun; 14(1):75. PubMed ID: 32564775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a "rare in rare" scenario.
    Danesin N; Scapinello G; Del Prete D; Naso E; Berno T; Visentin A; Bonaldi L; Martines A; Bertorelle R; Vianello F; Gurrieri C; Zambello R; Castellani C; Fedrigo M; Rizzo S; Angelini A; Trentin L; Piazza F
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2062. PubMed ID: 38662353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.